Aura Biosciences (AURA) Projected to Post Earnings on Monday

Aura Biosciences (NASDAQ:AURA) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Aura Biosciences Stock Performance

AURA stock traded up $0.83 during mid-day trading on Monday, reaching $6.77. 290,169 shares of the stock traded hands, compared to its average volume of 214,276. Aura Biosciences has a one year low of $4.34 and a one year high of $7.73. The stock has a market capitalization of $429.85 million, a PE ratio of -3.49 and a beta of 0.45. The business has a 50-day moving average price of $5.54 and a two-hundred day moving average price of $5.85.

Insider Activity

In other news, CTO Mark Plavsic sold 15,890 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.05, for a total value of $80,244.50. Following the transaction, the chief technology officer directly owned 181,397 shares in the company, valued at approximately $916,054.85. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Los Pinos Elisabet De sold 47,648 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $241,098.88. Following the completion of the transaction, the insider directly owned 409,815 shares in the company, valued at $2,073,663.90. This represents a 10.42% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 123,076 shares of company stock valued at $618,783. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its stake in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after acquiring an additional 2,104 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Aura Biosciences by 12.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock worth $152,000 after purchasing an additional 2,693 shares during the period. Barclays PLC increased its holdings in Aura Biosciences by 6.7% during the 4th quarter. Barclays PLC now owns 69,298 shares of the company’s stock worth $378,000 after purchasing an additional 4,366 shares during the period. Intech Investment Management LLC raised its position in Aura Biosciences by 35.9% during the 4th quarter. Intech Investment Management LLC now owns 20,993 shares of the company’s stock valued at $114,000 after purchasing an additional 5,541 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Aura Biosciences by 29.3% in the 4th quarter. MetLife Investment Management LLC now owns 25,031 shares of the company’s stock worth $136,000 after buying an additional 5,674 shares during the period. 96.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AURA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, December 29th. Evercore started coverage on shares of Aura Biosciences in a research note on Tuesday, November 25th. They issued an “outperform” rating for the company. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.